Adagene CEO Will Lead Conference Chat October 15
Peter Luo of San Diego-based Adagene will discuss clinical programs at an upcoming biotech industry conference.
Updated on Oct. 14, 2026 in Biotech
Adagene CEO and President of R&D Peter Luo will participate in a fireside chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference on October 15, 2026. The session will focus on the biotechnology company's current clinical development and programs.
Why it matters
The fireside chat provides a venue for the clinical-stage firm to offer updates on its research initiatives, including its work with Dynamic Precision Library technology platforms and its ongoing Phase 1b/2 and Phase 2 studies of the anti-CTLA-4 SAFEbody, Muzastotug.
Adagene utilizes its proprietary Dynamic Precision Library technology platforms for drug development. Its candidate Muzastotug, an anti-CTLA-4 SAFEbody, is currently undergoing active evaluation in both Phase 1b/2 and Phase 2 clinical trials.
The players
Peter Luo
He serves as the Chief Executive Officer and President of R&D at the clinical-stage biotechnology company Adagene.
Adagene
This biotechnology company, which maintains corporate locations in San Diego and Suzhou, focuses on developing novel antibody-based therapies.
The details
The virtual event is slated to occur from 1:30 p.m. to 2:00 p.m. ET. Following the conclusion of the session, a recording will be made available for 30 days on the firm's investor portal.
Timeline
October 15, 2026, marks the date of the virtual conference participation.
The fireside chat session is scheduled from 1:30 p.m. to 2:00 p.m. ET.
A webcast of the session will be accessible for 30 days after the event.
The Tech Race
The use of advanced platforms like Adagene's Dynamic Precision Library technology represents a broader industry shift toward antibody discovery that replaces traditional, slower development models. This positions clinical-stage firms to compete more effectively in the high-stakes sector of immune cell engagement.
Investors and those tracking the biotechnology sector can access the session webcast through the company investor portal for 30 days following the conference. This provides a direct channel for stakeholders to monitor the progression of clinical programs without attending the live event.
The takeaway
The upcoming session offers transparency regarding the firm's clinical progress for shareholders and industry analysts. Interested individuals should prepare to access the webcast promptly to ensure they review the content before the 30-day availability period expires.
What happens next
The fireside chat will take place on October 15, 2026, with an archived version expected to be available on the company website for the following 30 days.
Further reading
For more on industry developments in this sector, visit the Biotech section.
More information
Interested parties can review corporate information via the Adagene investor relations website.
Source note: This article includes information reported by The Manila times.
